StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 1.2
Power Rank trend -> Rising
04/25/2025 14:16:00 EST
Danaher Corporation (DHR)
Industry: Diagnostics & Research
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, DHR has been trading in a range between $212.48 and $174.64 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Danaher Corporation $DHR entered a Red zone 56 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $284.4269, a potential upside of 52.24% from the recent price of 186.83. The stock is trading 50.23% (potential upside) below its 52 week high of $280.67 and 9.26 % (potential downside) above its 52 week low of $171.00 - based on the recent price.
Company Summary
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
News
| BLCO or DHR: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now? Source: Zacks Investment Research Wed, 23 Apr 2025 12:40:38 -0400 Sentiment: Positive |
| Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments. Source: Zacks Investment Research Tue, 22 Apr 2025 13:15:37 -0400 Sentiment: Neutral |
| Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript Danaher Corporation (NYSE:DHR ) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Tycho Peterson - Jefferies Scott Davis - Melius Research Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Rachel Vatnsdal - JPMorgan Daniel Brennan - TD Cowen Daniel Arias - Stifel Operator My name is Chelsy, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's First Quarter 2025 Earnings Results Conference Call. Source: Seeking Alpha Tue, 22 Apr 2025 11:09:47 -0400 Sentiment: Neutral |
| Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. Source: Zacks Investment Research Tue, 22 Apr 2025 10:36:39 -0400 Sentiment: Positive |
| How S&P 500 Stock Danaher Plans To Offset Tariffs After Its 'Solid' First-Quarter Report Danaher stock jumped Tuesday after the medical powerhouse delivered a "solid" first-quarter report and maintained its outlook for the year. Source: Investors Business Daily Tue, 22 Apr 2025 09:28:49 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 280.6687 52 Week Low: 171 Beta: 0.895 50 Day MA: 202.1958 200 Day MA: 238.9617 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.09 Qtr Revenue Growth YOY: -0.009 Forward PE: 25.7069 Trailing PE: 38.0814